BioNTech (NASDAQ:BNTX - Get Free Report) had its target price boosted by equities research analysts at JPMorgan Chase & Co. from $92.00 to $93.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage currently has a "neutral" rating on the stock. JPMorgan Chase & Co.'s target price indicates a potential upside of 14.54% from the company's current price.
A number of other analysts also recently weighed in on the stock. UBS Group reduced their target price on shares of BioNTech from $135.00 to $125.00 and set a "buy" rating on the stock in a research report on Wednesday, November 4th. Morgan Stanley dropped their price objective on shares of BioNTech from $114.00 to $106.00 and set an "overweight" rating on the stock in a research note on Wednesday, November 4th. Wells Fargo & Company cut their price objective on shares of BioNTech from $140.00 to $125.00 and set an "overweight" rating on the stock in a report on Wednesday, November 4th. Canaccord Genuity Group decreased their target price on shares of BioNTech from $136.00 to $132.00 and set a "buy" rating for the company in a research note on Wednesday, October 14th. Finally, Wall Street Zen upgraded shares of BioNTech from a "sell" rating to a "hold" rating in a report on Saturday, November 7th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $120.44.
Read Our Latest Analysis on BNTX
BioNTech Trading Down 2.5%
Shares of NASDAQ BNTX traded down $2.07 during midday trading on Thursday, hitting $81.19. 918,537 shares of the company traded hands, compared to its average volume of 1,088,011. BioNTech has a 12-month low of $79.52 and a 12-month high of $124.00. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.52 and a current ratio of 8.55. The stock has a 50-day moving average price of $92.14 and a 200 day moving average price of $95.45. The firm has a market cap of $20.53 billion, a P/E ratio of -11.87 and a beta of 1.28.
Insiders Place Their Bets
In other news, CEO Ugur Sahin sold 36,209 shares of the stock in a transaction on Friday, October 9th. The stock was sold at an average price of $95.37, for a total transaction of $3,453,252.33. Following the transaction, the chief executive officer directly owned 36,209 shares of the company's stock, valued at $3,453,252.33. This represents a 50.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 807,209 shares of company stock worth $79,246,837. 19.20% of the stock is currently owned by insiders.
Hedge Funds Weigh In On BioNTech
Institutional investors and hedge funds have recently made changes to their positions in the business. Liontrust Investment Partners LLP purchased a new stake in shares of BioNTech in the 3rd quarter worth $209,000. Virtu Financial LLC bought a new position in BioNTech in the 3rd quarter worth $1,265,000. Aristides Capital LLC lifted its position in BioNTech by 13.8% during the third quarter. Aristides Capital LLC now owns 12,281 shares of the company's stock valued at $1,207,000 after purchasing an additional 1,491 shares in the last quarter. Soleus Capital Management L.P. bought a new stake in BioNTech during the third quarter valued at about $246,000. Finally, Bellevue Group AG grew its holdings in BioNTech by 17.7% during the third quarter. Bellevue Group AG now owns 24,980 shares of the company's stock valued at $2,456,000 after purchasing an additional 3,751 shares during the period. Hedge funds and other institutional investors own 15.52% of the company's stock.
BioNTech Company Profile
(
Get Free Report)
BioNTech SE is a biotechnology company based in Mainz, Germany. Founded in 2008, it develops medicines and vaccines, with a focus on immunotherapies for cancer and infectious diseases. The company's research uses technologies including messenger RNA (mRNA), antibodies, and cell-based therapies. Its best-known product is Comirnaty, an mRNA vaccine against COVID-19 developed and commercialized in partnership with Pfizer. BioNTech also has a broad oncology research and development portfolio. BioNTech works with partners to develop and distribute products internationally.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider BioNTech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioNTech wasn't on the list.
While BioNTech currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.